|
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products
for the treatment of patients with cancer. Two major
programs anchor the Company's
research platform
: DNA/RNA-based Medicines and Small Molecules.
Genasense® (oblimersen sodium)
Injection is the Company's lead compound from its DNA/RNA
Medicines program. Genta is currently recruiting
patients to the
AGENDA
Trial
, a global Phase 3 trial of Genasense in patients with
advanced melanoma. The leading drug in Genta's Small
Molecule program is
Ganite® (gallium nitrate
injection),
which the Company is exclusively marketing in the U.S. for
treatment of symptomatic patients with cancer related
hypercalcemia that is resistant to hydration. The
Company has developed
G4544
, an oral formulation of the active ingredient in Ganite,
that has recently entered clinical trials as a potential
treatment for diseases associated with accelerated bone
loss. The Company is also developing
tesetaxel
, a novel, orally absorbed, semi-synthetic taxane that is
in the same class of drugs as paclitaxel and
docetaxel. Ganite and Genasense are available on a "
named-patient
" basis in countries outside the United States. For
more information about Genta, please visit our website at:
http://www.genta.com//
.
About the OTC Bulletin Board
The OTC Bulletin Board (OTCBB) is a regulated quotation
service that displays real-time quotes, last-sale prices,
and volume information in OTC equity securities. An OTC
equity security generally is any equity that is not listed
or traded on a national securities exchange. OTCBB
securities include national, regional, and foreign equity
issues, warrants, units, ADRs, and Direct Participation
Programs. More information is available at www.otcbb.com.
Certain quote display sites may require the addition of
".OB" following the trading symbol (e.g., GNTA.OB).
Safe Harbor
This press release may contain forward-looking
statements with respect to business conducted by Genta
Incorporated. By their nature, forward-looking statements
and forecasts involve risks and uncertainties because they
relate to events and depend on circumstances that will
occur in the future. Forward-looking statements
include, without limitation, statements about:
- the Company's ability to obtain necessary regulatory
approval for Genasense® from the U.S. Food and Drug
Administration ("FDA") or European Medicines Agency
("EMEA");
- the safety and efficacy of the Company's products or
product candidates;
- the Company's assessment of its clinical trials;
- the commencement and completion of clinical
trials;
- the Company's ability to develop, manufacture,
license and sell its products or product candidates;
- the Company's ability to enter into and successfully
execute license and collaborative agreements, if
any;
- the adequacy of the Company's capital resources and
cash flow projections, and the Company's ability to
obtain sufficient financing to maintain the Company's
planned operations;
- the adequacy of the Company's patents and proprietary
rights;
- the impact of litigation that has been brought
against the Company and its officers and directors and
any proposed settlement of such litigation;
- the Company's ability to retain compliance with the
NASDAQ's listing qualifications; and
- the other risks described under Certain Risks and
Uncertainties Related to the Company's Business, as
contained in the Company's Annual Report on Form 10-K and
Quarterly Report on Form 10-Q.
The Company does not undertake to update any
forward-looking statements. There are a number
of factors that could cause actual results and developments
to differ materially. For a discussion of those risks
and uncertainties, please see the Company's Annual Report
on Form 10-K for 2007 and its most recent quarterly report
on Form 10-Q.
SOURCE: Genta Incorporated
CONTACT:
Genta Investor Relations
908-286-3980
info@genta.com
|
